Effect of phenelzine, a monoamine oxidase inhibitor, on isoproterenol-induced myocardial damage.
The effect of phenelzine on isoproterenol-induced myocardial necrosis was studied in rats. Male albino rats were pretreated with 20 mg/kg body wt of phenelzine, intraperitoneally, on 4 consecutive days. The same animals were given 80 mg/kg of isoproterenol subcutaneously on the third and fourth days of the study. After 48 hr of isoproterenol, ECG was recorded, the animals were killed, and blood, heart, and adrenal glands were removed for biochemical and histopathological studies. Phenelzine returned toward normal the isoproterenol-induced decreased in cardiac glycogen but decreased serum lactic acid only slightly toward normal. The serum enzymes, serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT), showed the protective effect of phenelzine. The increase in isoproterenol-induced free fatty acid (FFA) was significantly reduced in the group pretreated with phenelzine. Our studies on adrenal ascorbic acid suggest that the animals pretreated with phenelzine suffered less stress compared to the group treated with isoproterenol alone. Histopathological changes including focal areas of necrosis and characteristic cellular exudation were less marked in the hearts of rats pretreated with phenelzine. S-T segment elevation was more marked in the group treated with isoproterenol only.
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D006321:Heart / Q000187:drug effects*; D007545:Isoproterenol / Q000494:pharmacology*; D008297:Male; D009203:Myocardial Infarction / Q000503:physiopathology; D009206:Myocardium / Q000378:metabolism / Q000473:pathology*; D009336:Necrosis; D010624:Phenelzine / Q000494:pharmacology*; D051381:Rats
D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D007545:Isoproterenol; D010624:Phenelzine